The expression of the immune checkpoint protein—programmed cell death protein 1 and its ligands (PD-1 and PD-L1)—in the tumor microenvironment supports the role of immune editing in breast cancer [7, 8]. This evidence concerns the gene PDCD1 and breast carcinoma.